Pfizer Oncology Medical
@PfizerOncMed
Followers
32K
Following
3
Media
1K
Statuses
1K
Pfizer sponsored. Posts are intended for US healthcare professionals (HCPs) only and may not be suitable outside the US. https://t.co/jHvCqeBej4
US
Joined September 2020
Visit Pfizer Oncology Medical at #ASH25 booth #1843 to discover our latest hematology research. Explore the congress program to learn more: https://t.co/LLCW9Ec8ZL
0
0
0
Discover how a new MAIC study compares androgen receptor pathway inhibitors in mHSPC, offering insights into treatment strategies and clinical outcomes. Read the full publication in Future Oncology: https://t.co/INH6afgtw3
0
1
0
As #ESMO25 ends, we’d like to thank everyone who visited Pfizer Oncology Medical! We’re inspired by the shared commitment to advancing oncology care and proud to have shared our latest research. If you missed us, explore our congress resources online: https://t.co/cEhjpsT8K1
0
1
0
Learn more about the long-term safety of an ALK tyrosine kinase inhibitor, including adverse event management, in patients with ALK+ advanced/metastatic non-small cell #LungCancer in the 5-year follow-up of this phase 3 study: https://t.co/WbWk3nPQol
0
0
1
A new publication from the Phase 2 PHAROS study highlights updated follow-up data on overall survival in adult pts with BRAF V600E-mutant metastatic non-small cell lung cancer. Read more: https://t.co/GSkhVeDpBF
0
0
3
Listen to this podcast to learn about treatments for metastatic/nonmetastatic hormone-sensitive #ProstateCancer, focusing on therapies that target the androgen-sensitive pathway. Explore patient-specific treatment selection and barriers to treatment: https://t.co/HCmlG6bKKE
0
0
0
Learn about dosing, pharmacokinetics, and potential drug interactions with an ARPI for the treatment of advanced #ProstateCancer in this podcast featuring hypothetical patient cases with real-world clinical implications: https://t.co/CZOx6QZbxM
0
1
0
Discover how reduced dosing frequency of a BCMA-CD3 bispecific antibody affects patient-reported outcomes in patients with relapsed/refractory #MultipleMyeloma in this phase 2 study: https://t.co/mEQwMBsLOQ
0
0
1
In this podcast, two oncologists and a nurse practitioner discuss strategies for managing treatment and adverse events for a nectin-4 ADC + PD-1 inhibitor in patients with locally advanced/metastatic #UrothelialCancer. Listen now: https://t.co/9IOJEVgFQN
0
0
1
See a comparison of patient-reported peripheral neuropathy in triple-class refractory #MultipleMyeloma in clinical trial patients receiving a BCMA-CD3 BsAb versus patients in a real-world study given physician’s choice of therapy: https://t.co/FXQOJgwxe8
0
0
1
Can AI improve how we conduct systematic reviews in oncology? A new publication shows how machine learning can enhance text screening for cardiotoxicity studies—boosting speed and sensitivity. Read more: https://t.co/iP1cBw87EG
0
0
0
Explore findings from this phase 3 trial at our mini oral presentation during #ESMO25 to learn more about the impact of adding a CDK4/6 inhibitor to HER2 and endocrine therapy on HRQoL after induction in HR+/HER2+ metastatic #BreastCancer: https://t.co/bgl51JfU8s
0
0
0
A new NEJM publication examines androgen receptor inhibition in biochemically recurrent #ProstateCancer. Learn how hormonal modulation may inform clinical decision-making. Read more: https://t.co/BT9i56W3n5
0
0
1
At #ESMO25, attend Pfizer Oncology Medical's proffered paper session for valuable insights into a ctDNA analysis of BRAF V600E dynamics in phase 3 study patients treated for BRAF V600E-mutant metastatic #ColorectalCancer: https://t.co/4EdGAIyKTY
0
0
2
Mark your schedule for these #ESMO25 poster presentations and explore the latest research from Pfizer Oncology Medical. You can find the full congress program here:
0
0
1
Visit Pfizer Oncology Medical at our #ESMO25 proffered paper session to explore overall survival in patients with biochemically recurrent #ProstateCancer treated with an androgen receptor pathway inhibitor https://t.co/Eej7jLZnU1
0
0
1
Explore findings from an updated overall survival analysis of phase 2 study patients with BRAF V600E-mutant metastatic #NSCLC receiving a BRAF V600E kinase inhibitor + MEK1/2 inhibitor at our mini oral presentation during #ESMO25: https://t.co/yxCfXRCdhk
0
0
4
Attend this proffered paper session at #ESMO25 to explore results from a phase 3 study of perioperative nectin-4-directed ADC + PD-1 inhibitor in patients with muscle-invasive #BladderCancer ineligible for platinum-based chemotherapy: https://t.co/TobguGZtk8
0
0
0
Join Pfizer Oncology Medical at #ESMO25! Visit our poster presentations on #GynecologicalCancer and #UrothelialCancer to learn how we're advancing cancer research. Explore the congress program here for more details:
0
0
0